For example, a large case-control study found that diabetic patients who received metformin had a significant lower risk of pancreatic cancer (odds ratio = 0.38; 95% CI: 0.22–0.69; P = 0.001) comparing to those who did not, while insulin administration caused a higher risk of pancreatic cancer [1]. This evidence concerns the gene INS and pancreatic neoplasm.